Biogen Idec Enters Genome-Editing Field with Sangamo BioSciences Collaboration
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 2 (Table of Contents)
Published: 4 Feb-2014
DOI: 10.3833/pdr.v2014.i2.2003 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a further validation of its zinc finger nuclease (ZFN) genome-editing platform, Sangamo BioSciences has formed a collaboration with Biogen Idec to develop potentially curative therapies for haemoglobinopathies, including sickle cell disease (SCD) and beta-thalassaemia (BT)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS